Skip to main content
Equibles

Shankar Musunuri

CEO

Ocugen, Inc. (OCGN)

Chairman

Ocugen, Inc. (OCGN)

Equibles does not estimate personal net worth.

Get an email with a short summary when Ocugen, Inc. publishes a filing, an earnings call transcript or a press release.

Get OCGN alerts

About Shankar Musunuri

Shankar Musunuri is recorded as CEO and Chairman at Ocugen, Inc. (OCGN). The newest filing on record that lists Shankar Musunuri as CEO at Ocugen, Inc. (OCGN) is dated April 28, 2026. The proxy statement of Ocugen, Inc. reports total compensation of $4,841,822 for Shankar Musunuri in fiscal 2025, including a base salary of $757,900. Disclosed compensation is on record for 7 fiscal years. Shankar Musunuri has spoken on 24 earnings calls and 2 other investor events across 1 company, most recently for Ocugen, Inc. on November 4, 2026. Ocugen, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ocugen, Inc. includes Quan Anh Vu (CFO), Ramesh Ramachandran (CFO and Chief Accounting Officer), Rita Johnson Green (CFO) and 5 others.

Shankar Musunuri on recent calls

“The third quarter was a quarter of execution for Archigen. We now have all three of our late-stage modified gene therapy programs in Phase III. We advanced our business development strategy, and we established a presence in Europe to support pre-commercial activities.”
Chairman, Ocugen, Inc. Third Quarter 2026 Financial Results and Recent Business Highlights ·
“I think, I mean, we as oxygen today, I believe we lead ophthalmology gene therapies. Why? We have three programs in late stage.”
Chairman, Canaccord 46th Annual Growth Conference ·
“The second quarter was a defining one for Ocigen. The FDA cleared our phase 3 trial for Ocufor 10 to initiate dosing in geographic atrophy patients and granted RMAP designation for the program.”
CEO, Ocugen, Inc. Q2 FY2026 Earnings Call ·
“We're really trying to bring this cutting edge technology to the market and also work harder to provide market access for patients who need them globally. Significant unmet medical need.”
Chairman, Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference ·
“Before I walk through the quarter, I want to discuss the $115 million offering of convertible senior nodes that we announced yesterday. With the recent offering, the company is expected to have cash, cash equivalents, and restricted cash of $112.1 million at closing, which includes the revenue debt payoff.”
CEO, Ocugen, Inc. Q1 FY2026 Earnings Call ·

Affiliation history

Company network

Leadership on record at Ocugen, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Ocugen, Inc. (OCGN) $757,900 $4,841,822
2024 Ocugen, Inc. (OCGN) $757,900 $1,941,539
2023 Ocugen, Inc. (OCGN) $757,900 $4,535,231
2021 Ocugen, Inc. (OCGN) $541,300 $8,141,351
2020 Ocugen, Inc. (OCGN) $500,000 $1,552,178
2019 Ocugen, Inc. (OCGN) $420,000 $572,320
2018 Ocugen, Inc. (OCGN) $420,000 $431,000

Recent activity

Show 14 earlier activities